NDAC open hearing
This article was originally published in The Tan Sheet
Executive Summary
Those wishing to speak during public comment section of Sept. 19-20 NDAC meeting on acetaminophen, NSAID, aspirin safety must submit their final statements to FDA by Sept. 4, along with full disclosure on potential conflicts of interest. Submissions should be labeled either "Open APAP," "Open NSAIDs" or "Open ASA," FDA advises, noting "we think separate submissions" on each type of analgesic "would be desirable, but you can use your own judgement." All statements will be posted on 1FDA's Web site before the meeting, agency adds...